A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2017
Price : $35 *
At a glance
- Drugs Taselisib (Primary)
- Indications Breast cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 12 Mar 2016 Results (n = 54) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 31 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2014 Planned number of patients changed from 36 to 56 according to ClinicalTrials.gov record.